{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:43Z","timestamp":1793465563629,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.esmoop.2023.102195","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:39:51Z","timestamp":1704947991000},"page":"102195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"title":["2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting"],"prefix":"10.1016","volume":"9","author":[{"given":"J.","family":"Herrstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Clark-Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Olver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Affronti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Garcia-Del-Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Celio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bosnjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.102195_bib1","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.102195_bib2","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102195_bib3","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.esmoop.2023.102195_bib5","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib6","first-page":"271","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents","volume":"25","author":"Jordan","year":"2017","journal-title":"Support Care Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2023.102195_bib7","first-page":"S43","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102195_bib10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib11","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.102195_bib12","doi-asserted-by":"crossref","first-page":"S1139","DOI":"10.1016\/j.annonc.2021.08.2144","volume":"32","author":"Shimomura","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102195_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A\u00a0randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102195_bib15","first-page":"5335","article-title":"Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy","volume":"28","author":"Ithimakin","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102195_bib17","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.31557\/APJCP.2022.23.6.2137","article-title":"Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist","volume":"23","author":"Sukauichai","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A\u00a0double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102195_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","article-title":"A\u00a0randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients","volume":"50","author":"Yeo","year":"2020","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib20","first-page":"277","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib21","first-page":"6225","article-title":"Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study","volume":"30","author":"Gao","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4143\/crt.2019.713","article-title":"Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly-emetogenic chemotherapy-induced nausea and vomiting","volume":"52","author":"Kang","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102195_bib23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1634\/theoncologist.2015-0128","article-title":"Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21","volume":"20","author":"Kim","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102195_bib24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib25","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/cam4.2979","volume":"9","author":"Matsumoto","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3904\/kjim.2020.359","article-title":"Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial","volume":"38","author":"Sun","year":"2023","journal-title":"Korean J Intern Med"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102195_bib27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00228-021-03157-2","article-title":"Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"77","author":"Hsu","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib28","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1078155218808084","article-title":"Infusion reactions following administration of intravenous rolapitant at an academic medical center","volume":"25","author":"Cass","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102195_bib29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cpdd.1183","article-title":"Challenges in the development of intravenous neurokinin-1 receptor antagonists: results of a safety and pharmacokinetics dose-finding, phase 1 study of intravenous fosnetupitant","volume":"11","author":"Tyler","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102195_bib30","first-page":"6649","article-title":"A\u00a0real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients","volume":"30","author":"Dranitsaris","year":"2022","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102195_bib31","article-title":"Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: a randomized, double-blind, phase III study","volume":"26","author":"Yang","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102195_bib32","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1002\/cncr.32429","article-title":"Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"125","author":"Sugawara","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy","volume":"29","author":"Schwartzberg","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib34","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102195_bib37","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.34088","article-title":"A\u00a0phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC","volume":"128","author":"Matsuura","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib38","first-page":"2699","article-title":"Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"27","author":"Herrstedt","year":"2019","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","article-title":"Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial","volume":"38","author":"Cao","year":"2020","journal-title":"Invest New Drugs"},{"issue":"31","key":"10.1016\/j.esmoop.2023.102195_bib40","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2017.72.2538","article-title":"Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase III trial (CLOG1302 study)","volume":"35","author":"Zhang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2023.102195_bib41","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/cncr.30054","article-title":"Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy","volume":"122","author":"Hesketh","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib43","first-page":"21","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis","volume":"26","author":"Jordan","year":"2018","journal-title":"Support Care Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102195_bib44","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2217\/fon-2017-0712","article-title":"Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis","volume":"14","author":"Zhang","year":"2018","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib45","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial","volume":"51","author":"Nishimura","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea","volume":"22","author":"Takemoto","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102195_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2023.102195_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101480","article-title":"Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial","volume":"49","author":"Cheng","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib49","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/cas.12675","article-title":"Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron","volume":"106","author":"Komatsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102195_bib50","first-page":"3317","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin","volume":"23","author":"Furukawa","year":"2015","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib51","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jog.12748","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: a randomized, multicenter, phase-II trial","volume":"41","author":"Matsuura","year":"2015","journal-title":"J\u00a0Obstet Gynaecol Res"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102195_bib52","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1093\/oncolo\/oyac060","article-title":"One-day versus three-day dexamethasone with NK1RA for patients receiving carboplatin and moderate emetogenic chemotherapy: a network meta-analysis","volume":"27","author":"Watanabe","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0300891619839301","article-title":"Short-course olanzapine to prevent delayed emesis following carboplatin\/paclitaxel for gynecologic cancer: a randomised study","volume":"105","author":"Celio","year":"2019","journal-title":"Tumori"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2016.4096","article-title":"Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk","volume":"3","author":"Okuyama","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102195_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1078155214524809","article-title":"Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital","volume":"21","author":"Caracuel","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102195_bib56","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.31557\/APJCP.2020.21.6.1567","article-title":"Adherence to ASCO for prophylaxis of acute chemotherapy- induced nausea and vomiting in Iran","volume":"21","author":"Ebrahimi","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102195_bib57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s13187-020-01689-2","article-title":"Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Tehran","volume":"36","author":"Nikbakht","year":"2021","journal-title":"J\u00a0Cancer Educ"},{"issue":"14","key":"10.1016\/j.esmoop.2023.102195_bib58","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1002\/cam4.2486","article-title":"Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database","volume":"8","author":"Bun","year":"2019","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib59","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.21873\/anticanres.15154","article-title":"Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nab-paclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer","volume":"41","author":"Ohata","year":"2021","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib60","first-page":"2633","article-title":"Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)","volume":"20","author":"Hesketh","year":"2012","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00432-013-1540-z","article-title":"Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity","volume":"140","author":"Vig","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102195_bib62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s12094-016-1583-0","article-title":"SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)","volume":"18","author":"de Las Penas","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","article-title":"Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens","volume":"19","author":"Stiff","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"30","key":"10.1016\/j.esmoop.2023.102195_bib64","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","article-title":"Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial","volume":"32","author":"Schmitt","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib65","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"Clemmons","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102195_bib66","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00277-022-04877-w","article-title":"Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study","volume":"101","author":"Ye","year":"2022","journal-title":"Ann Hematol"},{"issue":"32","key":"10.1016\/j.esmoop.2023.102195_bib67","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"Albany","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102195_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2023.102195_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/595894","article-title":"Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting","volume":"2015","author":"Navari","year":"2015","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib70","first-page":"607","article-title":"A\u00a0randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation","volume":"25","author":"Nakagaki","year":"2017","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib71","first-page":"3439","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1188\/13.ONF.163-170","article-title":"Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"40","author":"Lee","year":"2013","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102195_bib73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/nure.12016","article-title":"Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review","volume":"71","author":"Marx","year":"2013","journal-title":"Nutr Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/SPC.0000000000000135","article-title":"Is ginger beneficial for nausea and vomiting? An update of the literature","volume":"9","author":"Marx","year":"2015","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10408398.2013.865590","article-title":"Ginger-mechanism of action in chemotherapy-induced nausea and vomiting: a review","volume":"57","author":"Marx","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102195_bib76","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.jand.2019.06.009","article-title":"Efficacy of ginger (Zingiber officinale) in ameliorating chemotherapy-induced nausea and vomiting and chemotherapy-related outcomes: a systematic review update and meta-analysis","volume":"119","author":"Crichton","year":"2019","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102195_bib77","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ptr.6377","article-title":"The effect of ginger (Zingiber officinale) on chemotherapy-induced nausea and vomiting in breast cancer patients: a systematic literature review of randomized controlled trials","volume":"33","author":"Saneei Totmaj","year":"2019","journal-title":"Phytother Res"},{"issue":"23","key":"10.1016\/j.esmoop.2023.102195_bib78","first-page":"01526","article-title":"Effect of a standardized ginger root powder regimen on chemotherapy-induced nausea and vomiting: a multi-center double-blind placebo-controlled randomized trial","volume":"S2212-2672","author":"Crichton","year":"2023","journal-title":"J\u00a0Acad Nutr Diet"},{"key":"10.1016\/j.esmoop.2023.102195_bib79","article-title":"Efficacy of auricular acupressure in prevention and treatment of chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and meta-analysis","volume":"2021","author":"Chen","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.esmoop.2023.102195_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijnurstu.2017.02.014","article-title":"Effects of acupressure on chemotherapy-induced nausea and vomiting-a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials","volume":"70","author":"Miao","year":"2017","journal-title":"Int J Nurs Stud"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctim.2014.11.002","article-title":"Effect of self-acupressure for symptom management: a systematic review","volume":"23","author":"Song","year":"2015","journal-title":"Complement Ther Med"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102195_bib82","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jpainsymman.2007.10.019","article-title":"Review of acupressure studies for chemotherapy-induced nausea and vomiting control","volume":"36","author":"Lee","year":"2008","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102195_bib83","doi-asserted-by":"crossref","first-page":"383","DOI":"10.12968\/bjcn.2004.9.9.15936","article-title":"Acupressure for nausea and vomiting in cancer patients receiving chemotherapy","volume":"9","author":"Klein","year":"2004","journal-title":"Br J Community Nurs"},{"key":"10.1016\/j.esmoop.2023.102195_bib84","article-title":"Effectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib85","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1200\/JCO.2012.43.5818","article-title":"Systematic review of acupuncture in cancer care: a synthesis of the evidence","volume":"31","author":"Garcia","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102195_bib86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/NCC.0b013e3181f104bc","article-title":"Cochrane review summary for cancer nursing: acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","volume":"33","author":"Konno","year":"2010","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.esmoop.2023.102195_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/430796","article-title":"Current evidence on auricular therapy for chemotherapy-induced nausea and vomiting in cancer patients: a systematic review of randomized controlled trials","volume":"2014","author":"Tan","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/acu.2020.1431","article-title":"Electrical stimulation of PC 6 to control chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and meta-analysis","volume":"33","author":"Garcia","year":"2021","journal-title":"Med Acupunct"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102195_bib89","first-page":"413","article-title":"Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review","volume":"31","author":"Molassiotis","year":"2023","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102195_bib90","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.clnu.2022.08.003","article-title":"Dietary strategies for chemotherapy-induced nausea and vomiting: a systematic review","volume":"41","author":"Gala","year":"2022","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102195_bib91","first-page":"4051","article-title":"Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials","volume":"28","author":"Tian","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.explore.2017.10.008","article-title":"Investigating the effects of the progressive muscle relaxation-guided imagery combination on patients\u00a0with cancer receiving chemotherapy treatment: a systematic review of randomized controlled trials","volume":"14","author":"Kapogiannis","year":"2018","journal-title":"Explore (NY)"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102195_bib93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2009.11.001","article-title":"A\u00a0prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres","volume":"94","author":"Maranzano","year":"2010","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/apm.2016.12.01","article-title":"Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2017","journal-title":"Ann Palliat Med"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102195_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.21037\/apm.2018.03.12","article-title":"A\u00a0pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting","volume":"7","author":"Ganesh","year":"2018","journal-title":"Ann Palliat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102195_bib96","first-page":"329","article-title":"The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting","volume":"20","author":"Emami","year":"2015","journal-title":"J\u00a0Res Med Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102195_bib97","first-page":"1503","article-title":"Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)","volume":"25","author":"Ades","year":"2017","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102195_bib98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)00615-4","article-title":"Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial","volume":"17","author":"Ruhlmann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102195_bib99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.12788\/jcso.0245","article-title":"Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting","volume":"14","author":"Navari","year":"2016","journal-title":"J\u00a0Community Support Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923014369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923014369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:33Z","timestamp":1761856293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923014369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2059702923014369"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102195"}}